KIF6: A Potential Drug Target and Biomarker for Cancer (G221458)

Target Name: KIF6

NCBI ID: G221458

KIF6: A Potential Drug Target and Biomarker for Cancer

KIF6, also known as KIF6 variant 1, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a member of the Kallikrein-related peptidases (KAPs) family, which includes a variety of structurally similar proteins that play important roles in various physiological processes.

One of the unique features of KIF6 is its ability to induce cell death, both in cancer cells and normal cells, through a process called apoptosis. This process is regulated by a variety of factors, including the production of pro-inflammatory cytokines.

KIF6 has also been shown to play a role in the regulation of cell proliferation, and has been shown to inhibit the activity of the oncogene transforming growth factor (TGF-β). This suggests that KIF6 may have potential as a drug target for the treatment of cancer.

In addition to its potential as a drug target, KIF6 has also been shown to be a potential biomarker for several types of cancer, including breast, ovarian, and colorectal cancers. This is because it is often overexpressed in these types of cancer, and can be used as a marker for the disease.

Overall, KIF6 is a protein that has significant potential as a drug target and biomarker, and is being actively targeted by researchers to study its role in various physiological processes. Further research is needed to fully understand the effects of KIF6 on cancer cell growth and the use of KIF6 as a drug.

Protein Name: Kinesin Family Member 6

More Common Targets